Evidence map›Paper›PMID 36803695›Full record

ReviewBiochimie2023

Structure and function of prodrug-activating peptidases.

José A Velilla, Grace E Kenney, Rachelle Gaudet

Open access · hybridAbstract readReview
In one paragraph

Review in Biochimie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

José A VelillaDepartment of Molecular and Cellular Biology, Harvard University, 52 Oxford St, Cambridge, MA, 02138, USA.
Grace E KenneyDepartment of Chemistry and Chemical Biology, Harvard University, 38 Oxford St, Cambridge, MA, USA.
Rachelle GaudetDepartment of Molecular and Cellular Biology, Harvard University, 52 Oxford St, Cambridge, MA, 02138, USA. Electronic address: gaudet@mcb.harvard.edu.
Harvard University · US

Funding

Mechanism of Divalent Metal Transport by NRamp-Family TransportersR01GM120996 · NIGMS · HARVARD UNIVERSITY · PI GAUDET, RACHELLE · 2017 to 2024
$3.0M
NIGMS NIH HHS R01 GM120996
6 · The paper itself

Abstract

Bacteria protect themselves from the toxicity of antimicrobial metabolites they produce through several strategies. In one resistance mechanism, bacteria assemble a non-toxic precursor on an N-acyl-d-asparagine prodrug motif in the cytoplasm, then export it to the periplasm where a dedicated d-amino peptidase hydrolyzes the prodrug motif. These prodrug-activating peptidases contain an N-terminal periplasmic S12 hydrolase domain and C-terminal transmembrane domains (TMDs) of varying lengths: type I peptidases contain three transmembrane helices, and type II peptidases have an additional C-terminal ABC half-transporter. We review studies which have addressed the role of the TMD in function, the substrate specificity, and the biological assembly of ClbP, the type I peptidase that activates colibactin. We use modeling and sequence analyses to extend those insights to other prodrug-activating peptidases and ClbP-like proteins which are not part of prodrug resistance gene clusters. These ClbP-like proteins may play roles in the biosynthesis or degradation of other natural products, including antibiotics, may adopt different TMD folds, and have different substrate specificity compared to prodrug-activating homologs. Finally, we review the data supporting the long-standing hypothesis that ClbP interacts with transporters in the cell and that this association is important for the export of other natural products. Future investigations of this hypothesis as well as of the structure and function of type II peptidases will provide a complete account of the role of prodrug-activating peptidases in the activation and secretion of bacterial toxins.

Indexed as

Escherichia coli ProteinsProdrugsEscherichia coliPeptide HydrolasesEscherichia coli ProteinsPeptide HydrolasesProdrugsBacterial toxinBeta-lactamaseMembrane-embedded peptidaseNon-ribosomal peptide synthesisProdrug resistance mechanismSequence similarity network

Identifiers

PMID36803695
PMCPMC10030199
OpenAlexW4308596780

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.